OCT 29, 2026 · JOURNAL ARTICLE
Longitudinal plasma osimertinib concentrations during treatment in patients with EGFR-mutant NSCLC: a prospective real-world study
Japanese Journal of Clinical Oncology
Abstract Background Osimertinib is used across treatment settings for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Dose reduction is sometimes